Treatment on retinopathy of prematurity
10.3760/cma.j.issn.2095-0160.2020.01.016
- VernacularTitle: 早产儿视网膜病变的治疗
- Author:
Siwen FANG
1
;
Xiang MA
Author Information
1. Department of Ophthalmology, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China
- Publication Type:Review
- Keywords:
Retinopathy of prematurity;
Pathogenesis;
Therapy;
Anti-vascular endothelial growth factor drug
- From:
Chinese Journal of Experimental Ophthalmology
2020;38(1):77-80
- CountryChina
- Language:Chinese
-
Abstract:
Retinopathy of prematurity (ROP) as a leading cause of blindness in children in both developed and developing countries, is a type of proliferative retinopathy that occurs in preterm and low birth mass infants.Early treatment can effectively save the visual function of the children.With the continuous study of the pathogenesis of ROP, the treatment is constantly changing.Due to its feasibility and complications, cryotherapy is not the priority.Laser therapy is still the golden standard, while there are inevitable complications.The efficacy of anti-vascular endothelial growth factor (VEGF) drugs among the numerous factors related to ROP is a satisfactory.Nowdays, the selection of drugs and the optimal injection dose are the key points.Meanwhile, the occurrence of systemic adverse events remains urgent.ROP pathogenesis, the advantages and disadvantages of several treatment methods were briefly described and summarized to providing references for the ROP treatment.
